TY - JOUR
T1 - Circadian Rhythm Sleep–Wake Disorders
T2 - a Contemporary Review of Neurobiology, Treatment, and Dysregulation in Neurodegenerative Disease
AU - Steele, Tyler A.
AU - St Louis, Erik K.
AU - Videnovic, Aleksandar
AU - Auger, R. Robert
N1 - Funding Information:
This publication was supported by NIH/NCRR/NCATS CCaTS Grant Numbers UL1 TR002377, NIH/NIA R34AG056639 (NAPS), NIH/NINDS R01NS099055, and NIH/NINDS R21NS108022.
Funding Information:
We gratefully acknowledge the contributions of Jim Soular of Flathead Valley Community College for providing valuable feedback on grammar and semantics on earlier drafts of the manuscript. We are also grateful to Ms. Lea Dacy, Mayo Clinic Department of Neurology, for secretarial assistance with manuscript formatting and submission. Disclosure forms provided by the authors are available with the online version of this article.
Publisher Copyright:
© 2021, The American Society for Experimental NeuroTherapeutics, Inc.
PY - 2021/1
Y1 - 2021/1
N2 - Circadian rhythms oscillate throughout a 24-h period and impact many physiological processes and aspects of daily life, including feeding behaviors, regulation of the sleep-wake cycle, and metabolic homeostasis. Misalignment between the endogenous biological clock and exogenous light–dark cycle can cause significant distress and dysfunction, and treatment aims for resynchronization with the external clock and environment. This article begins with a brief historical context of progress in the understanding of circadian rhythms, and then provides an overview of circadian neurobiology and the endogenous molecular clock. Various tools used in the diagnosis of circadian rhythm sleep–wake disorders, including sleep diaries and actigraphy monitoring, are then discussed, as are the therapeutic applications of strategically timed light therapy, melatonin, and other behavioral and pharmacological therapies including the melatonin agonist tasimelteon. Management strategies towards each major human circadian sleep–wake rhythm disorder, as outlined in the current International Classification of Sleep Disorders – Third Edition, including jet lag and shift work disorders, delayed and advanced sleep–wake phase rhythm disorders, non-24-h sleep–wake rhythm disorder, and irregular sleep–wake rhythm disorder are summarized. Last, an overview of chronotherapies and the circadian dysregulation of neurodegenerative diseases is reviewed.
AB - Circadian rhythms oscillate throughout a 24-h period and impact many physiological processes and aspects of daily life, including feeding behaviors, regulation of the sleep-wake cycle, and metabolic homeostasis. Misalignment between the endogenous biological clock and exogenous light–dark cycle can cause significant distress and dysfunction, and treatment aims for resynchronization with the external clock and environment. This article begins with a brief historical context of progress in the understanding of circadian rhythms, and then provides an overview of circadian neurobiology and the endogenous molecular clock. Various tools used in the diagnosis of circadian rhythm sleep–wake disorders, including sleep diaries and actigraphy monitoring, are then discussed, as are the therapeutic applications of strategically timed light therapy, melatonin, and other behavioral and pharmacological therapies including the melatonin agonist tasimelteon. Management strategies towards each major human circadian sleep–wake rhythm disorder, as outlined in the current International Classification of Sleep Disorders – Third Edition, including jet lag and shift work disorders, delayed and advanced sleep–wake phase rhythm disorders, non-24-h sleep–wake rhythm disorder, and irregular sleep–wake rhythm disorder are summarized. Last, an overview of chronotherapies and the circadian dysregulation of neurodegenerative diseases is reviewed.
UR - http://www.scopus.com/inward/record.url?scp=85103538365&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103538365&partnerID=8YFLogxK
U2 - 10.1007/s13311-021-01031-8
DO - 10.1007/s13311-021-01031-8
M3 - Review article
C2 - 33844152
AN - SCOPUS:85103538365
SN - 1933-7213
VL - 18
SP - 53
EP - 74
JO - Neurotherapeutics
JF - Neurotherapeutics
IS - 1
ER -